Feb 12, 2025

Dr. Sean Ianchulev, CMO, previously CEO of Iantrek, is developing a new approach to treating glaucoma, which involves a biologic implant that can be customized to the patient's disease progression. This technology is designed to be more durable compared to traditional glaucoma treatments, which often require lifelong use of eye drops. This treatment is a combination of microinterventional technology with biologic tissue technology to transform the approach to eye care.

Sean explains, "So we are a first not only for ophthalmology but also for medicine. We are the first, made of biologic technology, and we're to implant that tissue without any hardware, which is important because it minimizes implantable response. We can treat glaucoma patients who need intraocular pressure opening by opening and stenting the outflow pathway in a very unprecedented way. So, we've created a new categorical treatment, which we call bio-interventional."  

"I think in cataract, we can say we've probably been able to cure that disease by cataract surgery and have a permanent cure. Unfortunately, glaucoma is difficult, affecting the optic nerve. And when you talk about neurodegenerative diseases, we're not yet there where we can cure them, but if we can slow them down, and we can slow them down to the point where it does not impact somebody's well-being and vision until the end of their lifespan, I think that's almost equivalent to cure because we've been able to enable them to have a productive life."

#Iantek #Glaucoma #Innovation #Biointerventional #Microinterventional #Biotissue #EyeCare #Ophthalmology 

iantrekmed.com

Listen to the podcast here